Advice
in the absence of a submission from the holder of the marketing authorisation:
pembrolizumab (Keytruda®) is not recommended for use within NHSScotland.
Indication under review: As monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice361KB (PDF)
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2143
- Indication:
- As monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy.
- Pharmaceutical company
- MSD
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 December 2018